Edelweiss is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1390 in its research report dated November 06, 2017.
Edelweiss' research report on Torrent Pharmaceuticals
Rural Electrification Corporation’s (REC) Q2FY18 PAT at ~INR12bn came below estimate due to muted NII traction following NIMs pressure (lower incremental lending yields as health of stressed utilities is improving, in general and REC, in particular is relatively more focused on better rated utilities). REC has been following RBI norms from FY15 and overall asset quality held in good stead—GNPLs remained flat QoQ though S4A was invoked in a private project (Ratan India) with exposure of INR7.5 bn. Over the last few quarters, large part of stress emanated from known accounts and total stress pool (NNPAs + restructured) fell to 12.5% (13.2% in FY17). Business momentum was steady, with >10% YoY loan growth. Management maintained stance of potential upgradations starting Q3FY18 that will potentially help improve performance going ahead. At CMP, the stock trades at 0.8x FY19E P/BV for RoE of 15‐16%, rendering favourable risk‐reward. Maintain ‘BUY’ with TP of INR231.
REC has not sprung any negative surprise with respect to stress in state utility projects. However, key monitorable is its private sector exposure, though, in our view, significant recognition is unlikely over near term. Also, with UDAY scheme already being effected, we see better growth visibility for FY18-19. Despite NIM pressure, as incremental spreads are lower with structural improvement across power value chain, it has potential to deliver ~15-16% RoE, rendering favourable risk-reward. We maintain ‘BUY/SO’.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.